FDA

FDA Approves Twice-Yearly HIV Prevention Drug

Today marks a monumental advance in HIV prevention. Congratulations to the many researchers who spent nineteen years to get to today’s approval, backed up by the long-term investment needed to get the drug to market. Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.

read more

FDA proposes to lift discriminatory blood donation ban for gay men

HIV+Hep’s Carl Schmid issued the following statement: “This marks a monumental shift and ends a long and painful era of blanket discrimination against gay men. No longer will eligibility to donate blood be based on sexual orientation.  Instead, every person, no matter their sexuality, will be reviewed individually in order to determine their eligibility to donate.  While this long-overdue change is being made based on the science and the facts, which have been clear for years, it is the result of the leadership of the Biden administration that continues to tear down discriminatory government policies.”

read more

Pin It on Pinterest